Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-28
2006-02-28
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C514S019300
Reexamination Certificate
active
07005418
ABSTRACT:
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one ore more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided.
REFERENCES:
patent: 5658884 (1997-08-01), Hodgen
patent: 5663145 (1997-09-01), Engel et al.
patent: 0 943 336 (1999-09-01), None
patent: WO 97 27863 (1997-08-01), None
patent: WO 98/55470 (1998-12-01), None
patent: WO 00/55190 (2000-09-01), None
Nachtigall et al., Chapter 41, Danforth's Obstetrics and Gynecology, 1994, p. 757-769.
Reissmann et al. (Reissmann 1994), “Introduction of LHRH-Antagonists Into The Treatment of Gynaecological Disorders,” Human Reproduction, vol. 9, No. 5, pp. 767-769 (1994).
Reissmann et al. (Reissmann 1995), “Development and Applications of Luteinizing Hormone-Releasing Hormone Antagonists in the Treatment of Infertility: An Overview,” Human Reporudction, vol. 10, No. 8, pp. 1974-1981 (1995).
Kettel et al. (Kettel), “Rapid Regression of Uterine Leiomyomas in Response to Daily Administration of Gonadotroin-Releasing Hormone Antagonist,” Fertility and Sterility, vol. 60, No. 4, pp. 642-646 (1993).
Norman, P., “Cetrorelix, ASTA Medica AG”, Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs, vol. 2, No. 2, pp. 227-248, XP-000982761.
Th. Reissmann et al., Human Reproduction vol. 10, No. 8, pp. 1974-1981.
International search report.
Smetnik et al., Nonsurgical Gynecology (Saint Petersbury, Sotis) 2:89-93 (1995).
Diedrich Klaus
Engel Jurgen
Felberbaum Ricardo
Küpker Wolfgang
Riethmuller-Winzen Hilde
Hui San-Ming
Pillsbury Winthrop Shaw & Pittman LLP
Zentaris GmbH
LandOfFree
Method for the therapeutic management of extrauterine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the therapeutic management of extrauterine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the therapeutic management of extrauterine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3672060